Legend’s Pipeline Is Starting To Matter (NASDAQ:LEGN)
· seekingalpha.com
Legend Biotech is transitioning from a capital-intensive biotech to a profitable, CARVYKTI-driven commercial cell therapy company. See why LEGN stock is a Buy.
I think this 2Q26 call really goes to show that Legend Biotech Corporation ( LEGN ) is hitting an inflection point. That is, they're transitioning from a capita...